JAGX Stock Overview
A commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Jaguar Health, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.22 |
| 52 Week High | US$43.20 |
| 52 Week Low | US$3.07 |
| Beta | 0.90 |
| 1 Month Change | -77.88% |
| 3 Month Change | -44.22% |
| 1 Year Change | -88.14% |
| 3 Year Change | -99.98% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Jaguar Health, Inc. (NASDAQ:JAGX) Might Not Be As Mispriced As It Looks After Plunging 49%
May 24
Jaguar Health, Inc. (NASDAQ:JAGX) Shares Fly 55% But Investors Aren't Buying For Growth
Mar 29Jaguar Health, Inc. (NASDAQ:JAGX) Not Doing Enough For Some Investors As Its Shares Slump 39%
Jan 22Positive Sentiment Still Eludes Jaguar Health, Inc. (NASDAQ:JAGX) Following 32% Share Price Slump
Jun 10Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt
Jan 23Jaguar Health rises 19% on orphan drug tag for congenital diarrheal disorder treatment
Oct 17Jaguar Health sells crofelemer and lechlemer royalty rights for $4M upfront
Aug 25Jaguar Health gets 180-day grace period to regain compliance with Nasdaq's listing rule
Aug 19Jaguar Health rises on U.S. patent for treating chemotherapy-induced diarrhea
Aug 09Jaguar stock rises on license deal with SynWorld for Canalevia in China
Jun 29Jaguar Health CEO Lisa Conte - From Rainforest To Laboratory
Mar 07Jaguar Health shares jumps 13% after pricing $15M direct offering
Jan 13Jaguar Health plans for conditional marketing application in Europe for Crofelemer, initially for Long-Hauler COVID-19 patients
Jan 11Jaguar Health leaps higher in new year
Jan 05Jaguar Health inks second Mytesi royalties agreement for $6M
Dec 23Does Jaguar Health (NASDAQ:JAGX) Have A Healthy Balance Sheet?
Dec 02
Jaguar Health's crofelemer development nears SPAC funding in Europe, shares +61%
Nov 30Jaguar Health EPS misses by $0.10, misses on revenue
Nov 16Jaguar Health receives positive Nasdaq listing determination
Oct 29Shareholder Returns
| JAGX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -8.9% | 0.02% | -0.6% |
| 1Y | -88.1% | 15.2% | 22.5% |
Return vs Industry: JAGX underperformed the US Pharmaceuticals industry which returned 15.2% over the past year.
Return vs Market: JAGX underperformed the US Market which returned 22.5% over the past year.
Price Volatility
| JAGX volatility | |
|---|---|
| JAGX Average Weekly Movement | 36.6% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: JAGX's share price has been volatile over the past 3 months.
Volatility Over Time: JAGX's weekly volatility has increased from 25% to 37% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 49 | Lisa Conte | jaguar.health |
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products.
Jaguar Health, Inc. Fundamentals Summary
| JAGX fundamental statistics | |
|---|---|
| Market cap | US$20.63m |
| Earnings (TTM) | -US$38.32m |
| Revenue (TTM) | US$10.14m |
2.0x
P/S Ratio-0.5x
P/E RatioIs JAGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JAGX income statement (TTM) | |
|---|---|
| Revenue | US$10.14m |
| Cost of Revenue | US$2.12m |
| Gross Profit | US$8.02m |
| Other Expenses | US$46.34m |
| Earnings | -US$38.32m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.84 |
| Gross Margin | 79.07% |
| Net Profit Margin | -377.95% |
| Debt/Equity Ratio | 224.5% |
How did JAGX perform over the long term?
See historical performance and comparison